da Silva Filho Antônio Oliveira, Gonçalves Daniel Nazário, de Lima Letícia Karina Ramos, da Silva Alves Dâmocles Aurélio Nascimento, de Andrade Falcão Felipe José, Falcão Rosângela Estevão Alves
Post-Graduate Program in Health and Socio-Environmental Development Multicampi Garanhuns, University of Pernambuco, Garanhuns 55294-310, Brazil.
Department of Health Sciences, Multicampi Garanhuns, University of Pernambuco, Garanhuns 55294-310, Brazil.
Vaccines (Basel). 2023 Mar 9;11(3):620. doi: 10.3390/vaccines11030620.
Maternal vaccination is safe and provides protection against COVID-19 in mothers and neonates, and it is necessary to evaluate its effect on the induction of immune responses through the levels of neutralizing antibodies present in maternal and neonatal blood.
An observational study with transversal analysis was carried out. Included in the research were neonates (<1 month) whose mothers had been immunized whilst pregnant with at least one dose of the vaccine BNT16b and had not shown any symptoms of COVID-19. The blood of the mothers and newborns was collected during the Guthrie test and sent to the laboratory for the detection of neutralizing antibodies against SARS-CoV-2.
A total of 162 pairs of mothers and neonates were analyzed with an average age of 26.3 ± 5.97 years and 13.4 ± 6.90 days, respectively. All samples collected present neutralizing antibodies with an average percentage of 91% in the mothers and 92% in the neonates. The most satisfactory immune response was observed in neonates and mothers vaccinated during the second trimester of gestation.
The vaccination of expectant mothers with the immunizer BNT162b2 has promoted a robust immunological response in both the mothers and the neonates.
孕产妇接种疫苗是安全的，可为母亲和新生儿提供针对新冠病毒的保护，有必要通过母婴血液中存在的中和抗体水平来评估其对诱导免疫反应的效果。
开展了一项横断面分析的观察性研究。研究纳入了母亲在孕期接种至少一剂BNT16b疫苗且未出现任何新冠病毒症状的新生儿（<1个月）。在新生儿筛查试验期间采集母亲和新生儿的血液，并送往实验室检测针对严重急性呼吸综合征冠状病毒2的中和抗体。
共分析了162对母婴，母亲平均年龄为26.3±5.97岁，新生儿平均年龄为13.4±6.90天。所有采集的样本均存在中和抗体，母亲中的平均比例为91%，新生儿中的平均比例为92%。在妊娠中期接种疫苗的新生儿和母亲中观察到最令人满意的免疫反应。
使用免疫制剂BNT162b2对孕妇进行疫苗接种，在母亲和新生儿中均引发了强烈的免疫反应。
